Sollpura

Novel, biotechnology-derived pancreatic enzyme replacement therapy for the potential treatment of exocrine pancreatic insufficiency due to cystic fibrosis and other conditions.

Learn more about Sollpura

Blisibimod

B-cell activating factor (BAFF) inhibitor for the potential treatment of IgA nephropathy.

Learn more about Blisibimod

LATEST NEWS

Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 Clinical Study of Sollpura.

READ MORE

Anthera Pharmaceuticals Provides Business Update and Reports 2017 Third Quarter Financial Results.

READ MORE